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chronic eye diseases. Our patient database was sorted by diagnosis
to identify the cGvHD subgroup in this cohort. The characteristics
of this sub-group were extracted by database analysis and retro-
spective chart review. Initial VFQ-25 scores in this subgroup, their
scores at 6-month follow-up, and change in score for those ﬁtted
with the scleral lenses will be reported.
Results: There were 16 patients with ocular surface disease from
cGvHD seen for scleral lens consultation from January through
June 2006. Demographic breakdown reveals M:F  12:4, with age
distribution as follows: 21-30, n 2; 31-40, n  3; 41-50, n 3;
51-60, n6; 61-70, n2. Prior conventional therapy is reported.
Mean baseline composite score on the VFQ-25 was 62 (range
35-91, n16); scale is 0 – 100, with 100 representing highest level
of function. Of these 16 patients, 13 were ﬁtted with scleral lenses.
Mean score for patients not ﬁtted was 74 (n3), whereas mean
score for patients ﬁtted was 59 (n13). Preliminary analysis of data
on patients who have reached the 6-month follow-up (n6) reveals
that each patient ﬁtted had improvement of function. Mean score
at 6 months is 70.5 (n6). Mean change in score for the 6 patients
for whom there is 6-month follow-up is 20.6 (n6), with range
from 2 to  45.
Conclusion: The ﬂuid-ventilated gas permeable scleral lens
prosthetic device improves visual function in patients with ocular
cGvHD unresponsive to conventional therapy.
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cGVHD, deﬁned as GVHD after day 100, is common, with an
impact on morbidity and survival. The limited/extensive cGVHD
classiﬁcation is not reproducible or prognostic for late non-relapse
mortality (NRM). Recently the NIH consensus criteria were pro-
posed, but the ability of these criteria to predict outcome of various
types of cGVHD is unknown.
Pts undergoing their 1st SCT from 1/01 to 12/03 were studied.
110 pts alive beyond day 100 met criteria for the study. GVHD
after day 100 was classiﬁed using NIH criteria into: persistent acute
GVHD (aGVHD) (assigned at day 100), recurrent aGVHD, de-
layed aGVHD, classic cGVHD, overlap GVHD (all assigned at
time of onset). Severity scores were assigned to pts with classic and
overlap GVHD at onset and clinical worsening. Overall survival
(OS) both from time of transplant and time of GVHD onset were
measured.
37 (34%) had no GVHD and 73 (66%) pts had GVHD. OS was
44% vs. 66% (no GVHD vs.GVHD, P0.026). Of 73 pts with
GVHD, 14 (19%) had limited and 59 (80%) had extensive
cGVHD. Pts with limited GVHD were reclassiﬁed as persistent
aGVHD (7%), recurrent aGVHD (29%), and classic CGVHD
(64%). Pts with extensive cGVHD were reclassiﬁed as persistent
(3%), delayed (3%), recurrent (31%), classic chronic (37%), and
overlap GVHD (26%). 31 (42%) had no subsequent clinical wors-
ening and 42 (58%) had subsequent clinical worsening of GVHD.
65% of pts with classic cGVHD (22/31) had worsening compared
to other types (20/42, 47%) (P0.046). Severity scores increased in
12/31 pts (39%) at time of subsequent clinical worsening. OS of pts
with various types of GVHD were signiﬁcantly different
(P0.0001). This was more apparent when pts with any acute
features of GVHD were compared with classic cGVHD (3-yr OS
47% vs. 66%, P0.0015). This effect persisted when survival was
measured from onset of GVHD (P0.0336). Severity at onset or
clinical worsening in pts with classic or overlap GVHD did not
impact survival. The 3-yr NRM (with relapse as a competing risk)
for the cohort was 21% and was not affected by the presence or
absence of GVHD, or subtypes of GVHD. Signiﬁcant variables
using Cox model with time dependent covariates were any
aGVHD feature after day 100 (HHR 5.27, P0.0004), and exten-
sive cGVHD (HR 0.28, P0.0041).
The OS with different NIH subtypes after day 100 from SCT
varies and is superior for pts with classic cGVHD. Global severity
score, within the limits of our study had no prognostic value with
respect to survival.
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The prognosis of steroid refractory acute graft-versus-host dis-
ease (SR-aGVHD) is poor with suboptimal responses to currently
available agents. The role of B- lymphocytes in the pathogenesis of
GVHD is unclear, but recent reports of successful responses to
Rituximab in patients with cGvHD support the hypothesis that a
coordinated B and T cell response is instrumental in cGVHD. The
contribution of B-cells to the pathogenesis of aGVHD, however, is
unknown. We now report 3 patients who received Rituximab with
complete response of severe acute GVHD. The ﬁrst patient (ta-
ble-1) was a 51 year old female who developed severe transplant-
associated thrombotic thrombocytopenic purpura (TA-TTP),
manifesting as seizure, encephalopathy, cerebral edema, renal fail-
ure, fever and thrombocytopenia, which failed to respond to
methyl prednisone and 26 sessions of plasmapharesis. Rituximab
for refractory TTP was initiated on day  58, while plasma
exchange was continued. Following 3 doses of weekly Rituximab,
there was resolution of TTP. At the time of initiation of Ritux-
imab, the patient also had active grade III aGVHD that was
refractory to steroids. GVHD improvement was noted from day
79 with complete resolution of aGVHD on day95. During the
course of Rituximab, steroids were progressively tapered. Beyond
100 days she had limited cGVHD involving skin that was well
controlled on oral prednisone at 10 mg/day. 100% donor chimer-
ism was present. Two additional patients with refractory aGVHD
(Table 1) were then treated. Complete resolution of aGVHD
occurred in 2 weeks, but did not begin until several days after
stopping previous inﬂiximab/daclizumab therapy. This observation
of complete aGVHD responses to Rituximab in 3 patients requires
conﬁrmation in larger trial but suggests that B cells contribute to
the pathogenesis of both acute and chronic GvHD.
Table-1: Patient and disease characteristics of 3 patients with steroid
refractory aGVHD
Patient
Age/Sex
Diagnosis
Stage
Allogeneic
transplant
Organ
involved
aGVHD
grade
Previous
GVHD
Therapy
Timing/doses
of Rituximab
aGVHD
response Outcome
51 F DLBCL Mel-Flu-Alem
MUD/PBSCT
Skin III,
Gut III,
Grade
III
Steroids
(6.4 gm)
day 58 3
doses
Complete
residual
limited
cGVHD
Died of sepsis on
day 160
39 F CML BC CY/TBI MRD/
PBSCT
Skin III,
Liver II,
Gut III,
Grade
III
Steroids
(3.6 gm)
Infliximab
x6
day 61 2
doses
Complete
resolution
Alive in mCr
39 M AML M-7 CY/TBI/Alem
MUD/PBSCT
Liver II,
Gut IV,
Grade
IV
Steroids
(7.2 gm)
Infliximab
x5
Daclizumab
x4
day 49 4
doses
Complete
resolution
Alive in CR
Abbreviation: GVHD graft versus host disease, aGVHD acute
graft versus host disease, cGVHD chronic graft versus host
disease, F female, M male, DLBCL diffuse large B cell
lymphoma, Mel melphalan, Flu Fludarabine, Alem ale-
mtuzumab, MUD matched unrelated donor, PBSCT pe-
ripheral blood stem cell transplant, CML chronic myeloid
leukemia, BC blast crisis, CY cyclophosphamide, TBI
total body irradiation, MRD matched related donor, MTX
methotrexate, CR complete remission, mCR molecular
complete remission.
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